$65.36
0.41[0.63%]
At close: Apr 26
$65.36
0[0.00%]
After Hours: 4:00PM EDT
ANI Pharmaceuticals
(NASDAQ:ANIP)ANI Pharmaceuticals Stock (NASDAQ:ANIP), Analyst Ratings, Price Targets, Predictions
ANI Pharmaceuticals Inc has a consensus price target of $57.8, established from looking at the 26 latest analyst ratings. The last 3 analyst ratings were released from Guggenheim, Capital One, and Guggenheim on April 23, 2024, March 15, 2024, and March 5, 2024. With an average price target of $51.33 between Guggenheim, Capital One, and Guggenheim, there's an implied -21.46% downside for ANI Pharmaceuticals Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Guggenheim
Capital One
HC Wainwright & Co.
Truist Securities
Raymond James
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for ANI Pharmaceuticals
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/23/2024 | ANIP | Buy Now | ANI Pharmaceuticals | $65.36 | 17.81% | Guggenheim | Vamil Divan | → $77 | Reiterates | Buy → Buy | Get Alert |
| 03/15/2024 | ANIP | Buy Now | ANI Pharmaceuticals | $65.36 | — | Capital One | Timothy Chiang | — | Initiates | → Overweight | Get Alert |
| 03/05/2024 | ANIP | Buy Now | ANI Pharmaceuticals | $65.36 | 17.81% | Guggenheim | Vamil Divan | $70 → $77 | Maintains | Buy | Get Alert |
| 03/04/2024 | ANIP | Buy Now | ANI Pharmaceuticals | $65.36 | 26.99% | HC Wainwright & Co. | Oren Livnat | $73 → $83 | Maintains | Buy | Get Alert |
| 03/01/2024 | ANIP | Buy Now | ANI Pharmaceuticals | $65.36 | 22.4% | Truist Securities | Gregory Fraser | $72 → $80 | Maintains | Buy | Get Alert |
| 02/16/2024 | ANIP | Buy Now | ANI Pharmaceuticals | $65.36 | 10.16% | Truist Securities | Gregory Fraser | $70 → $72 | Maintains | Buy | Get Alert |
| 10/19/2023 | ANIP | Buy Now | ANI Pharmaceuticals | $65.36 | 10.16% | Guggenheim | Vamil Divan | → $72 | Reiterates | Buy → Buy | Get Alert |
| 09/13/2023 | ANIP | Buy Now | ANI Pharmaceuticals | $65.36 | 10.16% | Guggenheim | Vamil Divan | → $72 | Reiterates | Buy → Buy | Get Alert |
| 08/22/2023 | ANIP | Buy Now | ANI Pharmaceuticals | $65.36 | 11.69% | HC Wainwright & Co. | Oren Livnat | $60 → $73 | Maintains | Buy | Get Alert |
| 08/21/2023 | ANIP | Buy Now | ANI Pharmaceuticals | $65.36 | 7.1% | Truist Securities | Gregory Fraser | → $70 | Reiterates | Buy → Buy | Get Alert |
| 08/10/2023 | ANIP | Buy Now | ANI Pharmaceuticals | $65.36 | 10.16% | Guggenheim | Vamil Divan | $62 → $72 | Maintains | Buy | Get Alert |
| 07/27/2023 | ANIP | Buy Now | ANI Pharmaceuticals | $65.36 | -5.14% | Guggenheim | Vamil Divan | $59 → $62 | Maintains | Buy | Get Alert |
| 07/21/2023 | ANIP | Buy Now | ANI Pharmaceuticals | $65.36 | -8.2% | Truist Securities | Gregory Fraser | $52 → $60 | Maintains | Buy | Get Alert |
| 05/09/2023 | ANIP | Buy Now | ANI Pharmaceuticals | $65.36 | -9.73% | Guggenheim | Vamil Divan | $55 → $59 | Maintains | Buy | Get Alert |
| 05/09/2023 | ANIP | Buy Now | ANI Pharmaceuticals | $65.36 | -20.44% | Truist Securities | Gregory Fraser | $50 → $52 | Maintains | Buy | Get Alert |
| 05/09/2023 | ANIP | Buy Now | ANI Pharmaceuticals | $65.36 | -25.03% | Raymond James | Elliot Wilbur | $48 → $49 | Maintains | Outperform | Get Alert |
| 05/09/2023 | ANIP | Buy Now | ANI Pharmaceuticals | $65.36 | -8.2% | HC Wainwright & Co. | Oren Livnat | $53 → $60 | Maintains | Buy | Get Alert |
| 03/13/2023 | ANIP | Buy Now | ANI Pharmaceuticals | $65.36 | -18.91% | HC Wainwright & Co. | Oren Livnat | $50 → $53 | Maintains | Buy | Get Alert |
| 03/01/2023 | ANIP | Buy Now | ANI Pharmaceuticals | $65.36 | -15.85% | Guggenheim | Vamil Divan | → $55 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for ANI Pharmaceuticals (ANIP)?
The latest price target for ANI Pharmaceuticals (NASDAQ: ANIP) was reported by Guggenheim on April 23, 2024. The analyst firm set a price target for $77.00 expecting ANIP to rise to within 12 months (a possible 17.81% upside). 17 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for ANI Pharmaceuticals (ANIP)?
The latest analyst rating for ANI Pharmaceuticals (NASDAQ: ANIP) was provided by Guggenheim, and ANI Pharmaceuticals reiterated their buy rating.
When was the last upgrade for ANI Pharmaceuticals (ANIP)?
There is no last upgrade for ANI Pharmaceuticals.
When was the last downgrade for ANI Pharmaceuticals (ANIP)?
There is no last downgrade for ANI Pharmaceuticals.
When is the next analyst rating going to be posted or updated for ANI Pharmaceuticals (ANIP)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ANI Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ANI Pharmaceuticals was filed on April 23, 2024 so you should expect the next rating to be made available sometime around April 23, 2025.
Is the Analyst Rating ANI Pharmaceuticals (ANIP) correct?
While ratings are subjective and will change, the latest ANI Pharmaceuticals (ANIP) rating was a reiterated with a price target of $0.00 to $77.00. The current price ANI Pharmaceuticals (ANIP) is trading at is $65.36, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.